In Brief: Mepron tablets
Executive Summary
Mepron tablets: Burroughs Wellcome will discontinue marketing the product following approval of an oral suspension formulation of the Pneumocystis carinii pneumonia treatment for AIDS patients intolerant to trimethoprim/sulfamethoxazole. The oral suspension has 58% higher oral bioavailability than the tablets, the company says. The dosing for Mepron (atovaquone) oral suspension is 750 mg per teaspoon two times daily...